Abstract
Three different aspects of myocardial protection during ischemia have lately received much attention. Metabolic and functional adaptation to moderate ischemia has been investigated in animal models of hibernation and might help clarify the pathophysiology of this important clinical feature of coronary artery disease. To further improve myocardial salvage by reperfusion, new anticoagulant agents are currently being tested as adjunctive therapy to thrombolysis. In this regard, new antagonists of the platelet glycoprotein llb/IIIA complex and new synthetic thrombin inhibitors appear very promising. Finally, increasing attention to the phenomenon of ischemic preconditioning may contribute to a better understanding of myocyte adaptation to ischemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
